EPM News Update
Hovione has announced a co-promotion and collaboration agreement with Ligand Pharmaceuticals to provide Hovione’s customers with efficient access to Captisol technology.
Captisol, a chemically modified cyclodextrin, is proven to improve the solubility and stability of drugs and is currently used in six marketed products. Hovione offers particle engineering technologies to improve the solubility of modern drugs. The agreement allows Hovione to use Captisol technology in its solubilisation programmes, which include amorphous solid dispersions, crystal design and size reduction and control of particle size. By adding this new technology, it increases the likelihood of solving the molecule’s bioavailability challenges.
“Hovione is delighted to announce the ability to provide access to Captisol.There is no single solution to improving bioavailability and for a customer to access diverse options with a single supplier provides for greater probability of success and speedier outcomes,” said Dr. Colin Minchom, Hovione’s Vice President of Particle Design.
“Hovione has manufactured Captisol for more than a decade and we are very pleased to expand our partnership to help customers succeed. Providing for greater access to Captisol should efficiently enable the successful development of more poorly soluble molecules and further increase our Captisol partnership portfolio,” said Mathew W. Foehr, Ligand’s Executive Vice President and Chief Operating Officer.
Hovione, +351 21 982 9362, ipina@hovione.com, www.hovione.com.